Chemistry Department, Menarini Ricerche S.p.A. Via Sette Santi 3, 50131 Florence, Italy.
ChemMedChem. 2010 Jan;5(1):65-78. doi: 10.1002/cmdc.200900389.
Herein we describe the synthesis of a series of new potent tachykinin NK(2) receptor antagonists by the modulation of the C- and N-terminal moieties of ibodutant (MEN 15596, 1). The N-terminal benzo[b]thiophene ring was replaced by different substituted naphthalenes and benzofurans, while further modifications were evaluated at the C-terminal tetrahydropyran moiety. Most compounds demonstrated a high affinity for the human NK(2) receptor and high in vitro antagonist potency, indicating that a wide range of substituents at both termini can be incorporated in the molecule without detrimental effects on the interactions with the NK(2) receptor. Selected compounds were tested in vivo confirming their activity as NK(2) antagonists. In particular, after both iv and id administration to guinea pig, compound 61 b was able to antagonize NK(2)-induced colonic contractions with a potency and duration-of-action fully comparable to the reference compound 1 (MEN 15596, ibodutant).
在此,我们描述了一系列新的强效速激肽 NK(2)受体拮抗剂的合成,方法是调节伊博特坦(MEN 15596,1)的 C 端和 N 端部分。用不同取代的萘和苯并呋喃取代 N 端苯并[b]噻吩环,同时在 C 端四氢吡喃部分进行进一步修饰。大多数化合物对人 NK(2)受体表现出高亲和力和高体外拮抗活性,表明在分子的两端可以引入广泛的取代基,而不会对与 NK(2)受体的相互作用产生不利影响。选择的化合物在体内进行了测试,证实了它们作为 NK(2)拮抗剂的活性。特别是,化合物 61b 在豚鼠体内 iv 和 id 给药后,能够拮抗 NK(2)诱导的结肠收缩,其效力和作用持续时间与参比化合物 1(MEN 15596,伊博特坦)完全相当。